Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence?

Wendling, Daniel

doi:10.1016/j.jbspin.2019.06.003

Cited by 16 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…That is the reason why the need of further study on IA glucocorticoid injection in SpA was highlighted in a recently published study. 21 Nonetheless, the effect of IA sacroiliac glucocorticoid injection on clinical improvement has been consistent across studies. From a placebo-controlled, double-blind study of 13 IA sacroiliac injections in 10 patients with SpA (glucocorticoid for 6 joints, normal saline for 7 joints), more patients in the steroid group described pain relief of at least 70% at 1 month (glucocorticoid 5/ 6; normal saline 0/7, p < 0.05).…”

Section: Discussionmentioning

confidence: 75%

Efficacy and Safety of Intra-articular Sacroiliac Glucocorticoid Injections in Ankylosing Spondylitis

Nam¹,

Kim²,

Lee

et al. 2020

J Clin Rheumatol

View full text Add to dashboard Cite

Background/Aims: To assess the efficacy and safety of intra-articular sacroiliac glucocorticoid injection in ankylosing spondylitis (AS).Methods: Patients with AS undergoing fluoroscopy-guided intra-articular sacroiliac glucocorticoid injection were enrolled between 2012 and 2018. Efficacy was assessed by numeric pain rating scale, acute phase reactants, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index, and Ankylosing Spondylitis Disease Activity Score (ASDAS). Patients who started biologics within 3 months despite the intervention were compared with those not starting biologics, hence: the nonbiologic group.Results: A total of 96 patients were treated, with a total of 107 injections.After intervention, there were significant decreases in numeric pain rating scale (7.8 ± 1.8 vs. 3.3 ± 2.2, p < 0.001) and acute phase reactants level (erythrocyte sedimentation rate [ESR] 23.0 mm/h [10.0-47.0 mm/h] vs. 13.0 mm/h [4.0-27.0 mm/h], p < 0.001; C-reactive protein [CRP] 1.0 mg/dL [0.2-2.7 mg/dL] vs. 0.2 mg/dL [0.2-0.9 mg/dL], p < 0.001). Disease activity scores also decreased for BASDAI (6.2 ± 1.8 vs. 4.5 ± 2.5, p = 0.001), Bath Ankylosing Spondylitis Functional Index (5.5 [4.1-7.0] vs. 1.8 [0.5-4.1], p = 0.001), ASDAS-CRP (2.9 ± 1.0 vs. 2.3 ± 1.3, p = 0.046), and ASDAS-ESR (3.7 ± 1.1 vs. 2.4 ± 1.3, p < 0.001). However, 12 patients (12.5%) started biologics within 3 months. These patients showed higher ESR (91.0 mm/h [IQR 21.0-113.0 mm/h] vs. 21.5 mm/h [IQR 9.5-43.0 mm/h], p = 0.010), CRP (8.0 mg/dL [IQR 1.11-17.1 mg/dL] vs. 0.8 mg/dL [IQR 0.2-1.8 mg/dL], p = 0.002), BASDAI (7.4 ± 1.2 vs. 5.9 ± 1.8, p = 0.027), and ASDAS-CRP (4.0 ± 0.5 vs. 2.8 ± 1.0, p = 0.004) than the nonbiologic group. There was no serious adverse event.Conclusions: Intra-articular sacroiliac glucocorticoid injection can be a safe and effective treatment option for active sacroiliitis in AS.

show abstract

Section: Discussionmentioning

confidence: 75%

Efficacy and Safety of Intra-articular Sacroiliac Glucocorticoid Injections in Ankylosing Spondylitis

Nam¹,

Kim²,

Lee

et al. 2020

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…However, the small sample size and short followup means that we cannot recommend this practice. Corticosteroid injections can be proposed to patients with axial pain, especially in the sacroiliac joints, with a transient effect on symptoms [76].…”

Section: 25mentioning

confidence: 99%

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Nur so werde effektiv eine schmerzhafte Pathologie des dorsalen Bandapparates behandelt. 2020 veröffentlichte Wendling [16] eine Arbeit über die Evidenz von Steroidinjektionen bei axialer Spondyloarthritis und berichtet über 80 % positive Ergebnisse über 8 Monate in offenen Studien, sogar über eine Reduktion von entzündlichen Zeichen im MRI nach Injektionen wird berichtet.…”

Section: Evidenzen In Der Literaturunclassified

Injektionstechniken am ISG bei axialer Spondylarthritis als Ergänzung zur manuellen Therapie

Schneider¹

2022

Arthritis und Rheuma

View full text Add to dashboard Cite

show abstract

Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence?

Cited by 16 publications

References 23 publications

Efficacy and Safety of Intra-articular Sacroiliac Glucocorticoid Injections in Ankylosing Spondylitis

Efficacy and Safety of Intra-articular Sacroiliac Glucocorticoid Injections in Ankylosing Spondylitis

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

Injektionstechniken am ISG bei axialer Spondylarthritis als Ergänzung zur manuellen Therapie

Contact Info

Product

Resources

About